TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical-stage company developing immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers, announced positive Phase 1a safety results for its lead candidate TTX-MC138 at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain. The data, presented in poster 1025P, showed that the trial met its primary safety endpoint with no dose-limiting toxicities observed across four dose levels ranging from 0.8 mg/kg to 4.8 mg/kg, administered once every 28 days. Dose-dependent plasma exposure was demonstrated across all evaluated doses, and the company also reported disease stabilization and extended progression-free intervals in a subset of patients.
The results are significant because they support continued clinical evaluation of TTX-MC138, which targets metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis. The ongoing multicenter, open-label study is evaluating safety, tolerability, pharmacokinetics, antitumor activity, and exploratory biomarkers in patients with previously treated advanced solid tumors. For a clinical-stage company like TransCode Therapeutics (NASDAQ: RNAZ), achieving a clean safety profile in early-stage testing is a critical milestone that reduces development risk and may attract further investment or partnership interest. The absence of dose-limiting toxicities and the evidence of disease stabilization suggest that TTX-MC138 could offer a tolerable treatment option for patients with advanced cancers, a population with limited therapeutic alternatives.
The announcement also highlights the potential of RNA-based therapeutics in oncology. By targeting microRNA-10b, TTX-MC138 aims to address the underlying mechanisms of metastasis, which is responsible for the majority of cancer-related deaths. If later-stage trials confirm these early findings, the therapy could represent a novel approach for treating metastatic disease. The full press release can be viewed at https://ibn.fm/g3E2F, and the latest news and updates relating to RNAZ are available in the company’s newsroom at https://ibn.fm/RNAZ.
The data were disseminated through InvestorWire, a specialized communications platform that is part of the Dynamic Brand Portfolio @ IBN. InvestorWire provides wire-grade press release syndication, editorial syndication to 5,000+ outlets, and social media distribution to help companies reach a wide audience of investors and media. The platform also offers press release enhancement and a full array of tailored corporate communications solutions. For full terms of use and disclaimers, visit https://www.InvestorWire.com/Disclaimer.
